Indian drugmakers are developing their versions of Novo Nordisk s weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy s, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.
“After the two weeks of confusion, this is a positive move for the sugar companies. The government allowing the industry to divert some amount of sugar juice towards ethanol, is clearly a positive move in terms of the profitability that would have happened otherwise if the ban would have remained. So, net-net, this is a positive move from a margin standpoint.”
Banks and NBFCs should ensure that credit growth at the overall, sectoral, and sub-sectoral levels remain sustainable and all forms of exuberance are avoided; credit risk should also be priced properly. Lenders are relying on ALM mismatch to sustain margins through overreliance on short-term bulk deposits.